To Get Full Access :

aBLA Filing Intelligence & Biosimilar Opportunity

Epkinly

Epcoritamab-Bysp
Anticancer
Injection

Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.

Approval Date
19-May-23
Data Exclusivity Expiry
19-May-27
Market Exclusivity Expiry
19-May-35
Commercial snapshot

Market performance & projections

Revenue ($M)
650
CAGR (%)
42.80%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
961
2027
1,516
2028
2,095
2029
2,703
2030
3,239
2031
3,787
2032
4,354
Molecule profile

Details & specifications

Molecule
Epcoritamab-Bysp
Innovator
GENMAB AND ABBVIE
Dosage Form
Injection
Strength
4 mg/0.8 mL and 48 mg/0.8 mL
Therapeutic Category
Anticancer
Usage
To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?